Boston Scientific Corporation (BSX) posted adjusted earnings per share (EPS) of 63 cents for the third quarter of 2024, up 26% from the year-ago figure. The figure beat the Zacks Consensus Estimate by 8.6% and also exceeded the company’s adjusted earnings per share guidance range of 57-59 cents per share.The quarter’s adjustments included certain amortization expenses, acquisition/divestitures-related net charges, and restructuring and restructuring-related charges, among others.Reported EPS for the third q ...

Financial Data and Key Metrics Changes - In Q3 2024, total company operational sales grew 19% and organic sales grew 18%, exceeding the guidance range of 13% to 15% [5][17] - Adjusted EPS for Q3 was $0.63, a 27% increase, surpassing the guidance range of $0.57 to $0.59 [5][17] - Adjusted operating margin for Q3 was 27.2%, expanding 110 basis points year-over-year [18] Business Line Data and Key Metrics Changes - Cardiology sales grew 29%, with Interventional Cardiology Therapies growing 14% [10] - Electrophysiology sales surged 177%, driven by commercial execution and increased procedure volumes [13] - Urology sales increased by 10%, with double-digit growth in Stone Management and Prostate Health [7][8] - Endoscopy sales grew 7% organically, with strong growth in the US [8] Market Data and Key Metrics Changes - US operational sales grew 24%, with double-digit growth in six of eight business units [6] - Europe, Middle East, and Africa (EMEA) grew 14% operationally, driven by above-market performance in Electrophysiology [6] - Asia Pacific sales grew 12% operationally, with strong performance in China and Australia [7] Company Strategy and Development Direction - The company continues to focus on category leadership through innovation and clinical evidence generation [5] - Plans to close the acquisition of Axonics in Q4 2024, enhancing the Urology business [8] - The company aims to outperform markets and achieve double-digit growth in adjusted earnings per share in 2025 [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining top-tier financial performance and highlighted strong momentum across the portfolio, particularly in AF solutions [5][6] - The company anticipates continued growth driven by new product launches and expanding market share in existing accounts [46][47] Other Important Information - The company expects full-year 2024 adjusted EPS to be in the range of $2.45 to $2.47, representing growth of 20% to 21% [21] - The operational tax rate for Q4 is expected to be approximately 13.5% [21] Q&A Session All Questions and Answers Question: Upcoming OPTION trial and its impact - Management highlighted the positive implications of the concomitant reimbursement for WATCHMAN and FARAPULSE, emphasizing the safety and efficiency of both procedures [26][27] Question: FARAPULSE results and market share expectations - Management expressed confidence in FARAPULSE exceeding the previously communicated range of 40% to 60% of global AF ablations by 2026 due to rapid adoption by physicians [29] Question: AVANT GUARD trial observations - Management reassured that the observations from the AVANT GUARD trial were not life-threatening and emphasized confidence in the overall safety and efficacy of the FARAPULSE system [43][71] Question: Capacity and supply chain concerns - Management confirmed there are no anticipated supply shortages for FARAPULSE, despite high demand [63] Question: 2025 market growth drivers - Management identified several tailwinds for growth in 2025, including new product launches and expanding market share in existing accounts [46][47]

For the quarter ended September 2024, Boston Scientific (BSX) reported revenue of $4.21 billion, up 19.3% over the same period last year. EPS came in at $0.63, compared to $0.50 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $4.03 billion, representing a surprise of +4.35%. The company delivered an EPS surprise of +8.62%, with the consensus EPS estimate being $0.58.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

Boston Scientific (BSX) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.62%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $0.58 per share when it actually produced earnings of $0.62, delivering a surprise of 6.90%.Over the last four qua ...

Boston Scientific Announces Results for Third Quarter 2024 Marlborough, Mass. (October 23, 2024) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational basis and 18.2 percent on an organic basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared ...

UKRAINE - 2021/06/17: In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the background. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesBoston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates. The company should continue to benefit fr ...

New FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with OPAL HDx™ Mapping System to provide visualization during pulsed field ablationMARLBOROUGH, Mass., Oct. 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the navigation-enabled FARAWAVE™ NAV Ablation Catheter for the treatment of paroxysmal atrial fibrillation (AF) and FDA 510(k) clearance for the new FARAVIEW™ Software, which will combi ...

The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.58 per share, indicating an increase of 16% compared to the year-ago period. Analysts forecast revenues of $4.03 billion, representing an increase of 14.4% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a co ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Considering buying BSX stock? Here’s what analysts think: Read More: ...

Boston Scientific (BSX) closed the most recent trading day at $87, moving +0.27% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.47%. On the other hand, the Dow registered a gain of 0.79%, and the technology-centric Nasdaq increased by 0.28%.Heading into today, shares of the medical device manufacturer had gained 5.15% over the past month, outpacing the Medical sector's loss of 4.27% and the S&P 500's gain of 3.48% in that time.The investment community wil ...